Wave (WVE) Q2 Revenue Drops 56%

Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company focused on RNA-based medicines, reported second-quarter earnings on July 30, 2025, for the period ending June 30. The company missed Wall Street expectations by a wide margin, delivering revenue of $8.7 million for Q2 2025 versus analyst forecasts of $13.2 million and an earnings per share (EPS) loss of $0.31 for Q2 2025, compared to the anticipated loss of $0.28. Revenue fell 55.8% in the second quarter of 2025 compared to the prior year period. Operating expenses rose compared to the same period in 2024 as well, with research and administrative spending increased year over year in Q2 2025, contributing to a higher net loss for the second quarter of 2025 compared to the prior year period. Despite these financial setbacks, the company reported continued pipeline and clinical progress, but the absence of new partnership income and the accelerated cash burn put the focus firmly on near-term trial results and strategy execution. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Wave Life Sciences is dedicated to developing RNA-based medicines using its proprietary PRISM platform. This technology enables the company to design stereopure oligonucleotides -- specialized, chemically controlled strands of nucleic acids -- allowing greater control over drug properties like efficacy and safety. By leveraging this approach, it aims to create therapies for a wide range of genetic disorders, from rare conditions to broader public health challenges.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool